You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

35 search results for: disease progression

Impact of Delayed EoE Diagnosis on <b>Disease</b> <b>Progression</b> and QoL

expert video

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

2 min

Gastroenterology

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

AAAAI 2023 | The Role of Type 2 Inflammation in EoE <b>Disease</b> <b>Progression</b> Throughout the Lifespan

expert video

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan

7 min

Type 2 Inflammation

Dr. Jonathan Spergel delves into the role of type 2 inflammation in the progression of EoE throughout the lifespan of patients.

EAACI 2023 | Pediatric Type 2 Inflammatory <b>Disease</b> <b>Progression</b>

expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

40 min

Type 2 Inflammation

Dr. Leonard Bacharier and Profs. Oscar Palomares and Stephan Weidinger explore shared features of type 2 pathophysiology in AD, asthma, and EoE, and disease burden in pediatric patients

ERS 2023 | <b>Progression</b> of Underlying <b>Disease</b> in Pediatric Severe Asthma

expert video

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

10 min

Pulmonology

Join pediatric asthma experts Prof. Giorgio Piacentini and Dr. Sharon Dell for an educational program on the topic of remission in pediatric asthma.

AAAAI 2023 | Pediatric Type 2 Inflammatory <b>Disease</b> <b>Progression</b>

expert video

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression

33 min

Type 2 Inflammation

Drs. Theresa Guilbert, Fred Ghali, and Jonathan Spergel examine the role of type 2 inflammation across different inflammatory diseases from childhood to adulthood

Gap in Care Leads to <b>Progression</b> of Fibrosis in EoE

expert video

Gap in Care Leads to Progression of Fibrosis in EoE

1 min

Gastroenterology

Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE

expert video

UEGW 2024 | WHY Is Long-Term Management of EoE Important?

10 min

Gastroenterology

Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.

expert video

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

41 min

Pulmonology

Join Prof. Monika Gappa and Dr. Leonard Bacharier as they explore the importance of lung function in pediatric asthma disease progression

expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

8 min

Dermatology

Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the <b>Progression</b> of Asthma in Children

expert video

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children

10 min

Type 2 Inflammation

Dr. Theresa Guilbert explores how type 2 inflammation contributes to impaired lung function in pediatric patients with asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region